Cited by 1,676Genetics, Aging, and Longevity in Model OrganismsPI3K/AKT/mTOR signaling in cancerAutophagy in Disease and Therapy

mTOR is a key modulator of ageing and age-related disease

Open access
Johnson, Simon C., Rabinovitch, Peter S., Kaeberlein, Matt·2013·Nature

Abstract

Many experts in the biology of ageing believe that pharmacological interventions to slow ageing are a matter of 'when' rather than 'if'. A leading target for such interventions is the nutrient response pathway defined by the mechanistic target of rapamycin (mTOR). Inhibition of this pathway extends lifespan in model organisms and confers protection against a growing list of age-related pathologies. Characterized inhibitors of this pathway are already clinically approved, and others are under development. Although adverse side effects currently preclude use in otherwise healthy individuals, drugs that target the mTOR pathway could one day become widely used to slow ageing and reduce age-related pathologies in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature11861

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The mTOR pathway is often inhibited during CR and mediates CR-induced health benefits in model organisms.

    “the mammalian target of rapamycin (mTOR) pathway, which is induced by amino acids, growth factors, and RT, is often inhibited during CR, and mediates CR-induced health benefits in model organisms [37].”

    From Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis (2018) · cites this paper as [37]

    The Dietary restriction section (page not provided) says dietary restriction reduces mTORC1 activity in invertebrates and some mammalian tissues. It says mTORC1 is thought to help mediate the resulting health and longevity benefits, and that reduced signalling probably contributes to them; the claim presents that role as established. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Rapamycin inhibits the production of SASP factors.

    “a well-known inhibitor of mTOR, rapamycin, inhibits the production of SASP factors”

    From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [121]

    The opening section identifies rapamycin as an mTORC1 inhibitor, and the Inflammation section reports anti-inflammatory effects in several settings. Neither section says that rapamycin inhibits production of senescence-associated secretory phenotype (SASP) factors; searches for “SASP” and “senescence-associated secretory phenotype” found no such passage. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Rapamycin's inhibition of SASP factors might explain its beneficial impact on longevity.

    “which might explain its beneficial impact on longevity [121,122].”

    From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [121]

    The ‘mTOR in mammalian ageing and healthspan’ section reports that rapamycin extends lifespan in mice. The paper does not say that rapamycin inhibits SASP factors or propose that such inhibition explains the longevity benefit; a search for ‘senescence-associated secretory phenotype’ found no supporting passage in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Metformin, like rapamycin, is known to inhibit mTOR signaling.

    “Of significance is that metformin, like rapamycin, is known to inhibit mTOR signaling, and the inhibition of the mTOR signaling pathway with rapamycin has been shown to extend lifespan in C. elegans, S. cerevisiae, and Drosophila melanogaster (fruit fly) (221–225).”
  • Inhibition of the mTOR signaling pathway with rapamycin has been shown to extend lifespan in C. elegans, S. cerevisiae, and Drosophila melanogaster.

    “Of significance is that metformin, like rapamycin, is known to inhibit mTOR signaling, and the inhibition of the mTOR signaling pathway with rapamycin has been shown to extend lifespan in C. elegans, S. cerevisiae, and Drosophila melanogaster (fruit fly) (221–225).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M.
Affiliations
  • University of Washington (US)
  • Guangdong Medical College (CN)
Corresponding author
Kaeberlein, Matt
Venue
Nature
Published
2013-01-16
Volume
493
Issue
7432
Pages
338-345
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2010583480
Cited by
1,676
References
100
Citations by year
2026: 87 · 2025: 82 · 2024: 117 · 2023: 121 · 2022: 113 · 2021: 164 · 2020: 136 · 2019: 140 · 2018: 125 · 2017: 133 · 2016: 136 · 2015: 119 · 2014: 131 · 2013: 72
FWCI
9.38
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01AG031108, T32AG000057, P01AG001751, R01AG039390, R01AG038550, P30AG013280)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
mTOR, aging, age-related diseases, lifespan extension, rapamycin, mTOR inhibitors, pharmacological interventions
MeSH terms
Aging, Animals, Humans, Insulin, Insulin-Like Growth Factor I, Longevity, Signal Transduction, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review